<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306146</url>
  </required_header>
  <id_info>
    <org_study_id>CAD9303-101</org_study_id>
    <nct_id>NCT04306146</nct_id>
  </id_info>
  <brief_title>Study of CAD-9303 in Subjects With Schizophrenia</brief_title>
  <acronym>Affinity-1</acronym>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 Oral Treatment in Subjects With Schizophrenia and Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadent Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadent Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consist of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)&#xD;
      cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety,&#xD;
      tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy&#xD;
      volunteer subjects. The remaining cohorts will be in participants with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in two Parts. Part 1 will consist of Single Ascending Dose (SAD)&#xD;
      cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety,&#xD;
      tolerability, and pharmacokinetics of CAD-9303. Part 2 will consist of Multiple Ascending&#xD;
      Dose (MAD) cohorts that will be randomized, double blind, and placebo-controlled to assess&#xD;
      the safety, tolerability, and pharmacokinetics of CAD-9303. The effects of CAD-9303 will be&#xD;
      explored on event-related potential (ERP), and on sensory and cognitive function. The first&#xD;
      SAD cohort will be in healthy volunteer subjects. The remaining cohorts will be in&#xD;
      participants with schizophrenia. Participants will meet specified eligibility criteria.&#xD;
&#xD;
      SAD Cohorts will be comprised of 8 subjects; 6 subjects will be administered CAD-9303, and 2&#xD;
      subjects will be administered matching placebo. MAD Cohorts will be comprised of 12 subjects;&#xD;
      9 subjects will be administered CAD-9303, and 3 subjects will be administered matching&#xD;
      placebo.&#xD;
&#xD;
      Potential subjects will undergo a screening period (up to 28 days), baseline assessments on&#xD;
      Day -3, -2 and -1, and dosing on Day 1 for SAD and Days 1 - 14 for MAD. A follow-up visit&#xD;
      will occur 7 days after the last dose. The total duration of individual subject participation&#xD;
      may be up to 5 weeks for SAD and 7 weeks for MAD, depending on the duration of the screening&#xD;
      period.&#xD;
&#xD;
      The study will assess safety by adverse events, vital signs, laboratory parameters (including&#xD;
      chemistry, hematology and urinalysis) and electroencephalogram (EEG); pharmacokinetics of&#xD;
      CAD-9303; and exploratory efficacy measures effects on neurophysiological biomarkers,&#xD;
      cognitive and negative symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess safety and tolerability of CAD-9303 in participants with schizophrenia and normal healthy volunteers (NHV)</measure>
    <time_frame>Day 1 through Day 7 Follow-up</time_frame>
    <description>Incidence of Adverse Events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>CAD-9303</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules of CAD-9303 will be administered as a single or multiple dose(s). The initial dose will be 3 mg up to 1000 mg total daily dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be provided in capsules and administered as a single or multiple dose(s).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAD-9303</intervention_name>
    <description>Capsules filled with CAD-9303 from 3 mg up to 1000 mg.</description>
    <arm_group_label>CAD-9303</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  For SAD Cohorts: able to tolerate washout from antipsychotic medications for the&#xD;
             duration of the planned cohort.&#xD;
&#xD;
          -  For MAD Cohorts: not taking an antipsychotic medication at screening and throughout&#xD;
             participation in the study or taking one antipsychotic medication at least 6 weeks&#xD;
             prior to screening and as a concomitant antipsychotic medication throughout&#xD;
             participation in the study.&#xD;
&#xD;
          -  Diagnosis of schizophrenia by Diagnostic and Statistical Manual of Mental Disorders&#xD;
             (DSM-V) criteria with duration of illness &gt; 1 year since diagnosis.&#xD;
&#xD;
          -  Clinical history of minimal, stable positive symptoms while under treatment with a&#xD;
             stable psychotropic regimen.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal findings on screening safety EEG or lifetime history of seizures or stroke.&#xD;
&#xD;
          -  Meets current criteria of any psychiatric diagnosis other than schizophrenia, or&#xD;
             lifetime history of any psychiatric diagnosis other than schizophrenia based upon the&#xD;
             Mini International Neuropsychiatric Interview (MINI).&#xD;
&#xD;
          -  Participants with moderate to severe extrapyramidal symptoms including tardive&#xD;
             dyskinesia (Simpson-Angus Scale&gt;6, any Abnormal Involuntary Movement Scale (AIMS) Item&#xD;
             1-7 &gt;2), and akathisia (Barnes Akathisia Rating Scale [BARS] Item 4 â‰¥1).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cadent Therapeutics (A Novartis Company)</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Voltattorni</last_name>
      <phone>562-304-1742</phone>
      <email>hannavoltattorni@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Wilkins</last_name>
      <phone>856-753-7335</phone>
      <phone_ext>705</phone_ext>
      <email>lwilkins@hritrials.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

